Compare Nuscale Power Corporation (SMR) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Nuscale Power Corporation trades at $7.13 (market cap $3.00B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 19.6× Nuscale Power Corporation's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuscale Power Corporation for 29 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SMR | TAK | |
|---|---|---|
Market Cap | $3.00B | $58.74B |
Volume | 43,143,109 | 3,110,994 |
Sector | Industrials | Health |
52-Week High | $53.43 | $19.05 |
52-Week Low | $7.32 | $13.23 |
Typical Hold Time | 29 Days | 0 Days |
Enterprise Value | $1.93B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR stock trades at $7.23, down 5.74% on the day, reflecting a bearish technical trend and weak financial performance. The company reported a net loss of $355.79 million in 2025 on revenue of $31.48 million, with a negative net income margin of -3,888.7%. Despite analyst consensus pointing to a $11.25 price target, recent news highlights an ongoing SEC investigation and intense competition in the small modular reactor market.
The outlook remains highly speculative, with significant execution risk and cash burn offsetting long-term potential in the nuclear energy sector. While institutional interest and a 50% buy rating suggest some optimism, the stock's high volatility and lack of profitability present substantial risks for investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
